Gilead wins reversal of $1.2B fine in CAR-T patent fight with Bristol Myers | Fierce Pharma

The legal tussle focuses on whether Gilead’s CD19-targeted CAR-T therapy Yescarta infringed upon a Juno patent that’s licensed from MSK. The three- …